|Chemical and physical data|
|Molar mass||265.285 g/mol|
|3D model (JSmol)|
Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.
- Ana Martinez; Carmen Gil (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.
- John E. Macor (2012). Annual Reports in Medicinal Chemistry. Academic Press. pp. 83–. ISBN 978-0-12-396492-2.
- Susan H. Fox; Jonathan M. Brotchie (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.
- Addex Therapeutics. "Dipraglurant-ER for dystonia".
- Dipraglurant-IR for Parkinson's disease levodopa-induced dyskinesia - Addex Therapeutics
- Dipraglurant-ER for dystonia - Addex Therapeutics
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|